Are Managed-Care Stocks Overvalued?
Consolidation activity in the sector will have a positive impact operationally, but the stocks are overpriced, says Morningstar's Vishnu Lekraj.
Consolidation activity in the sector will have a positive impact operationally, but the stocks are overpriced, says Morningstar's Vishnu Lekraj.
Vishnu Lekraj: Today, we will cover the managed-care sector, or MCO sector. These firms are the largest health insurers and control a significant portion of health-care spending in the U.S. Over the past year, there has been a huge increase in the stock prices for the major MCOs under our coverage, which consists of UnitedHealth (UNH), Aetna (AET), Anthem (ANTM), Cigna (CI), and Humana (HUM). These firms have outperformed expectations in the face of harsh headwinds; but more critically, the slew of consolidation activity among the major five has driven their stock prices by double digits over the past year.
Unfortunately, this has pushed many of the firms into overvalued territory in relation to our fair value estimates. The major merger activity has consolidated the major five MCOs into a major three, with Aetna buying Humana and Anthem buying Cigna. We believe these moves are a positive from an operational standpoint, but we also believe the market is overvaluing the expected synergies of these deals.
Accordingly, we would caution investors about making new equity positions within any of these players. While we are not pounding the table on any of the major five MCOs from a valuation standpoint, we would point investors to UnitedHealth if they are looking for exposure to the sector. United has historically been the group's outperformer, and we expect this trend to continue given its strong competitive positioning and economic moat.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals
and individual investors. These products and services are usually sold through
license agreements or subscriptions. Our investment management business generates
asset-based fees, which are calculated as a percentage of assets under management.
We also sell both admissions and sponsorship packages for our investment conferences
and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.